SLC5A2 and Hypoglycemia: Additionally, dapagliflozin is one of the few SGLT2 inhibitors with specific pediatric studies, and its independent mechanism of action is beneficial for patients with severe IR, promoting glucose excretion without a high risk of hypoglycemia [44–47].